Apigenin and other flavonoids are capable of modulating EGFR, an attractive therapeutic target, by inhibiting Axl mRNA and protein expression, as well as Axl promoter activity, in NSCLC cells (A549, NCI-H460) [211,219]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.